MGLL and fragile X syndrome: In this study, EEG assessment was used to test the efficacy of an endocannabinoid (eCB)-positive modulator, JZL-184, which inhibits monoacylglycerol lipase (MAGL) [31, 32], a hydrolase involved in 2-arachidonoyl-sn-glycerol (2-AG) degradation [33], as a potential therapeutic for FXS.